3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
3
Phase NA
2
Phase 2
2
Phase 3
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pain
5
Neoplasms
5
Pain, Intractable
3
Agnosia
3
Pain, Postoperative
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Spinal Stenosis
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Peripheral Nervous System Diseases
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Procedural
1
Neurotoxicity Syndromes
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mucositis
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Cyclophosphamide
149
Docetaxel
139
Paclitaxel
127
Trastuzumab
120
Tamoxifen
110
Capecitabine
104
Letrozole
92
Epirubicin
79
Doxorubicin
70
Anastrozole
70
exemestane
67
Fulvestrant
65
Fluorouracil
61
Radiotherapy
60
pertuzumab
40
Gemcitabine
39
Carboplatin
38
Vinorelbine
34
Goserelin
34
Bevacizumab
29
Zoledronic Acid
28
Methotrexate
28
Chemotherapy, Adjuvant
28
eribulin
27
Lapatinib
25
ribociclib
24
palbociclib
24
Drug Therapy
22
130-nm albumin-bound paclitaxel
20
pegfilgrastim
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Breast Neoplasms
×
Ketamine
×
Clear all
NCT00210210
2025-09-19
KETAMINE
Institut Bergonié
Phase 3
Completed
230 enrolled
6 charts